UBS AM
GLUE icon

UBS AM’s Monte Rosa Therapeutics GLUE Stock Holding History

UBS AM’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58M Buy
65,451
+46,172
+239% +$872K ﹤0.01% 2163
2026
Q1 		$317K Buy
19,279
+18,709
+3,282% +$358K ﹤0.01% 2649
2025
Q4 		$8.94K Buy
+570
New +$7.68K ﹤0.01% 2873
2025
Q3 		– Sell
-24,100
Closed -$109K – 2409
2025
Q2 		$109K Hold
24,100
– – ﹤0.01% 2586
2025
Q1 		$112K Buy
+24,100
New +$148K ﹤0.01% 2595
2024
Q4 		– Sell
-24,100
Closed -$128K – 2698
2024
Q3 		$128K Buy
24,100
+8,500
+54% +$42.9K ﹤0.01% 2776
2024
Q2 		$58.3K Buy
+15,600
New +$79.5K ﹤0.01% 2781

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS AM's GLUE Position: Q2 2026 in Review

UBS AM increased its Monte Rosa Therapeutics (GLUE) stake by 239% in Q2 2026, buying an estimated $872K and bringing the position to 65,451 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #2163.

UBS AM first reported a position in GLUE in Q2 2024 and has held it in 7 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • UBS AM held 65,451 shares of Monte Rosa Therapeutics worth $1.58M as of Q2 2026.
  • UBS AM bought 46,172 Monte Rosa Therapeutics shares in Q2 2026, an estimated $872K.
  • Monte Rosa Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2163 holding.
  • UBS AM first reported a position in Monte Rosa Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.